natgillin/translations-raw huggingface dataset:
The pharmaceutical composition of claim 7, wherein the pharmaceutical composition further comprises a drug selected from the group consisting of cell signal transduction inhibitors, mitosis inhibitors, alkylating agents, antimetabolites, antibiotics, growth factor inhibitors, cell cycle inhibitors, topoisomerase inhibitors, biological reaction modifiers, antihormonal agents, antiandrogen, cell differentiation/proliferation/survival inhibitors, apoptosis inhibitors, inflammation inhibitors and P-glycoprotein inhibitors. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 14, pri čemu farmaceutski pripravak nadalje sadrži aktivnu tvar izabranu iz skupine koja se sastoji od inhibitora transdukcije staničnog signala, inhibitora mitoze, alkilirajućih sredstava, antimetabolita, antibiotika, inhibitora faktora rasta, inhibitora staničnog ciklusa, inhibitora topoizomeraze, modifikatora biološke reakcije, antihormonalnih sredstava, antiandrogena, inhibitora stanično diferencijacije / proliferacije / preživljavanja, inhibitora apoptoze, inhibitora upale i inhibitora P-glikoproteina.
Use of a humanized anti-CD44 antibody, or antigen binding fragment thereof, for the manufacture of a medicament for the treatment of a head and neck squamous cell carcinoma (HNSCC) in a human, wherein said HNSCC is characterized by the expression of CD44 and wherein said humanized antibody comprises a VH domain having the amino acid sequence of SEQ ID NO:9 and a VL domain having the amino acid sequence of SEQ ID NO: 11, or comprises a VH domain having the amino acid sequence of SEQ ID NO: 10 and a VL domain having the amino acid sequence of SEQ ID NO:11. 
Uporaba humaniziranog protutijela anti-CD44, ili njegovog fragmenta koji se veže na antigen, koja je za proizvodnju lijeka za liječenje karcinoma pločastih stanica glave i vrata (HNSCC) kod ljudi, naznačena time, da navedeni HNSCC izražava CD44, pri čemu navedeno humanizirano protutijelo sadrži VH domenu koja ima aminokiselinsku sekvencu SEQ ID NO:9 i VL domenu koja ima aminokiselinsku sekvencu SEQ ID NO: 11, ili sadrži VH domenu koja ima aminokiselinsku sekvencu SEQ ID NO:10 i VL domenu koja ima aminokiselinsku sekvencu SEQ ID NO: 11.
Method for replicating, amplifying or sequencing a template DNA which comprises contacting said DNA with a reaction mixture comprising at least: the DNA polymerase chimera according to any of claims 1 to 12, a buffer, 
Metoda za repliciranje, amplifikaciju ili sekvenciranje predloška DNK koji sadrži spomenuti povezni DNK s reakcijskom smjesom koja sadrži najmanje: a) DNK polimerazu himera prema bilo kojem zahtjevu od 1 do 11, b) pufer, c) magnezijev klorid, d) početnicu, i nukleozidne trifosfate.
After wash of the column, the captured material was eluted with 35% PG. 
Nakon ispiranja kolone, uhvaćeni materijal eluiran je sa 35% PG-om.
In the second position, the inlet valve is closed and the outlet valve is open. 
U drugom položaju, ulazni ventil je zatvoren, a izlazni ventil je otvoren.
The pharmaceutical composition of claim 55, further comprising a therapeutically effective amount of a therapeutic agent selected from the group consisting of steroids, membrane stabilizers, 5LO inhibitors, leukotriene synthesis and receptor inhibitors, inhibitors of IgE isotype switching or IgE synthesis, IgG isotype switching or IgG synthesis, B-agonists, tryptase inhibitors, acetylosalicylic acid, COX inhibitors, methotrexate, anti-TNF drugs, rituxin and other B-cell targeting agents, THF-targeting agents, PD4 inhibitors, p38 inhibitors, PDE4 inhibitors, and antihistamines. 
Farmaceutski pripravak prema zahtjevu 55, naznačen time što nadalje sadrži terapeutski učinkovitu količinu terapeutskog sredstva odabranog iz skupine koju čine steroidi, membranski stabilizatori, inhibitori 5LO, inhibitori sinteze i receptori leukotriena i receptor, inhibitori zamjene izotipa IgE ili sinteze IgE, inhibitori zamjene izotipa IgG ili sinteze IgG, B-agonisti, inhibitori triptaze, acetilosalicilna kiselina, inhibitori COX, metotreksat, anti-TNF lijekovi, rituksin i druga sredstva za ciljanje B-stanica, sredstva za ciljanje THF, inhibitori PD4, inhibitori p38, inhibitori PDE4 i antihistaminici.
The four reconstructed telegrams at outputs OUT1a/b, OUT2a/b, OUT3a/b, OUT4a/b are then sent to comparing circuits 14a, 14b. 
Četiri rekonstruirana telegrama kod izlaza OUT1a/b, OUT2a/b, OUT3a/b, OUT4a/b se zatim šalju prema uspoređujućim komunikacijskim krugovima 14a, 14b.
A product comprising a recombinant human follicle stimulating hormone (FSH) for use in the treatment of infertility in a patient having serum AMH level of < 15 pmol/L, wherein the product is to be administered at a dose of, or equivalent to, 11-13 µg recombinant human FSH per day, 12 to 16 days after administration of a GnRH agonist. 
HR P20191437 T1 PATENTNI ZAHTJEVI Proizvod koji sadrži rekombinantni ljudski folikulostimulirajući hormon (FSH) za upotrebu u liječenju neplodnosti kod pacijenta koji ima razinu serum AMH <15 pmol/L, naznačen time da se proizvod daje u dozi od, ili ekvivalentnoj 11-13 ug rekombinantnog ljudskog FSH na dan, 12 do 16 dana nakon primjene GnRH agonista.
A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least: 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju, koji sadrži formulaciju matrice s produljenim otpuštanjem, gdje formulacija matrice s produljenim otpuštanjem sadrži sastav koji sadrži:
The effect of dextromethorphan on muscle relaxant and reflex inhibitory activities of tolperisone 
Učinak dekstrometorfana na sredstvo za relaksaciju mišića i djelovanje tolperisona kao inhibitora refleksa
An isolated IL-23p19 antibody, wherein said antibody binds to human IL-23p19 or a fragment thereof at an epitope comprising amino acid residues 93-102 of SEQ ID NO: 1. 
PATENTNI ZAHTJEVI 1. Izolirano IL-23p19 protutijelo, naznačeno time što se navedeno protutijelo veže za IL-23p19 ili za njegov ulomak na epitopu koji sadrži ostatke aminokiselina 93-102 SEQ ID NO: 1.
In order to achieve an adequate security level the data portion on the data sheet should be attached to the attachment portion in such a manner that these two cannot be detached from one another without leaving any visible traces. 
Da bi se postigao odgovarajući nivo sigurnosti, predio za podatke na listu za podatke trebao bi biti povezan s predjelom za povezivanje na takav način, da se ova dva ne mogu rastaviti jedan od drugoga, a da se pri tome ne ostavi bilo kakvi vidljivi tragovi.
The plant product according to claim 6 prepared from a barley plant, or part thereof, wherein the barley plant carries: 
Spoj sladovine sukladno zahtjevu 13, pri čemu je sladovina pripravljena od ječma, ili njegovog dijela, sukladno zahtjevu 16.
Suitable active compounds in the combination which may be mentioned by way of example and preferably are: ACE inhibitors, angiotensin II receptor antagonists, beta receptor blockers, calcium antagonists, PDE inhibitors, mineralocorticoid receptor antagonists, diuretics, aspirin, iron supplements, vitamin B12 and folic acid supplements, statins, digitalis (digoxin) derivatives, tumor chemotherapeutics and antibiotics. 
Medikament naznačen time da sadrži spoj kako je definiran u jednom od zahtjeva 1 do 6 u kombinaciji sa jednim ili više dodatnih aktivnih spojeva koji su odabrani iz skupine koja sadrži ACE inhibitore, antagoniste angiotenzin II receptora, blokatore beta receptora, antagoniste kalcija, PDE inhibitore, antagoniste mineralno-kortikoidnih receptora, diuretike, aspirin, nadomjeske željeza, vitamin B12 i nadomjeske folne kiseline, statine, derivate digitalisa (digoksinina), kemoterapijska sredstva za tumore i antibiotike.
This advantage is displayed mainly during the treatment of specific pathological situations in the colon region, such as infectious colitis, bacillary dysentery, diverticular disease and diverticulitis where the site-specificity and the tolerability of the formulations play a key role in the resolution of the pathology. 
Ova prednost vidljiva je većinom tijekom liječenja specifičnih patoloških promjena u predjelu kolona, kao što su infektivni kolitis, bacilarna dizenterija, divrtikularna bolest i divertikulitis kada mjesna specifičnost i tolerancija prema formulacijama imaju glavnu ulogu u izlječenju bolesti.
Coating can be carried out with an aqueous or organic solution or an aqueous dispersion of the film-forming substances. 
HR P20070322 T3 vodenom ili organskom otopinom ili s vodenom disperzijom tvari koja može načiniti tanku prevlaku.
In some further embodiments, the engineered polypeptide has at least about 90% sequence identity to SEQ ID NO:4; and an amino acid residue difference at position H307. 
(ili) modificirani polipeptid ima barem 90% identičnosti sekvence sa SEQ ID NO:4; 1 da je razlika u aminokiselinskom ostatku na poziciji H307, opcionalno gdje je razlika u aminokiselinskom ostatku H307G/Q/M; i/ili
It is calculated to give approximately 6.5 mg/cm2 dry polymer per tablet surface area. 
Izračunata je da bi dala približno 6.5 mg/cm" suhog polimera po površini tablete.
detecting the formation of the immunological complex; and 
detektiranja nastajanja imunološkog kompleksa; i
crimping the left and right wires proximate the exit end of the respective lanyard (36a, 36b) and providing slack of the wires (14a', 14b') inside the lanyards (36a, 36b). 
HR P20161200 T1 nabiranje lijeve žice i desne žice blizu izlaznog kraja odgovarajuće vrpce (36a, 36b) i osiguravanje labavosti žica (14a', 14b') unutar vrpci (36a, 36b).
The resulting pellet was resuspended in wash buffer and stored in liquid nitrogen before use. 
Rezultirajuća peleta se resuspendira u puferu za ispiranje i čuva u tekućem dušiku do uporabe.
The compound of claim 1, wherein D is defined as in option (i). 
2. Spoj patentnog zahtjeva 1, gdje je D definirano kao u opciji (1).
Another aspect is a pharmaceutical composition comprising a double-stranded nucleic acid molecule and drug carrier comprising a mixture of a retinoid and a lipid, wherein the double-stranded oligonucleotide compound comprising the structure (A1): 
(i) dvolančanu molekulu nukleinske kiseline i nosač lijekova, koji sadrži smjesu retinoida 1 lipida, gdje dvolančana molekula nukleinske kiseline ima strukturu (A1): (A1)
The method of item 12, wherein the target cell is a human pathogen, and the therapeutic specifically binds an epitope of the human pathogen. 
(a) humani patogen, a terapijsko antitijelo se specifično vezuje za epitop humanog patogena;
The pharmaceutically acceptable acid addition salts of the compounds of the formula (I) are those formed from acids which form non-toxic acid addition salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, sulphate, phosphate or acid phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate and gluconate salts. 
Farmaceutski prihvatljive adicione soli s kiselinama spojeva formule (I) su one soli koje su formirane iz kiselina koje spajaju ne-otrovne adicione soli s kiselinama koje sadrže farmaceutski prihvatljive anione, kao što su klorhidratne, bromhidratne, jodhidratne, sulfatne ili bisulfatne, fosfatne ili bifosfatne, acetatne, maleatne, laktatne, tartaratne, citratno, glukonatne i saharatne soli.
Such compounds include, without implying any limitation, peptides, proteins, nucleic acids, (therapeutically active) low molecular weight organic or inorganic compounds (molecular weight less than 5000, preferably less than 1000), sugars, antigens or antibodies, therapeutic agents already known in the prior art, antigenic cells, antigenic cellular fragments, cellular fractions; modified, attenuated or de-activated (e.g. chemically or by irridation) pathogens (virus, bacteria etc.) etc. 
Farmaceutski pripravak prema zahtjevu 3, naznačen time da dodatno sadrži barem jednu farmaceutski aktivnu komponentu poželjno odabranu iz skupine koju čine peptidi, proteini, nukleinske kiseline, (terapijski aktivni) organski ili anorganski spojevi niske molekularne težine koji imaju molekularnu težinu manju od 5000, šećeri, antigeni, protutijela, patogeni, oslabljeni patogeni, deaktivirani patogeni, (ljudske) stanice, stanični fragmenti ili frakcije i druga terapijska sredstva, koja su poželjno prilagođena da imaju poboljšana svojstva transfekcije, uključujući kompleksiranje s lipidima i/ili polikationskim spojevima, uključujući polikationske peptide.
The water is eliminated at reduced pressure and the resulting residue redissolved in CH2Cl2, filtered and dried over anhydrous Na2SO4. 
Vodu se odstrani pod smanjenim tlakom i dobiveni ostatak se ponovno otopi u CH2C1,, profiltrira i osuši preko bezvodnog Na250,.
Locking system (1) for locking a glass door panel (2) of a swing door in the event of fire in order to close off an opening between two spaces, comprising 
Sustav za zabravljivanje (1), namijenjen zabravljivanju staklenog panela za vrata (2) njišućih vrata u slučaju požara, kako bi se zatvorilo otvor između dvije prostorije, koji ima .
The pharmaceutical composition according to any one of claims 8 to 14 for the treatment and/or prevention of dysfunctions of the circulatory system, preferably cardiovascular and/or coronary dysfunctions. 
Farmaceutski sastav prema bilo kojem zahtjevu 8 do 14, naznačen time, da se on upotrebljava za liječenje i/ili prevenciju disfunkcije cirkulacijskog sistema, ponajprije kardiovaskularne i/ili koroname disfunkcije.
In one embodiment of the invention the first or the second antigen is human TWEAK. 
(33) Država ili organizacija podnošenja prve prijave: EP 30.07.2014.
"alkyl" refers to a saturated hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms; 
"alkil" označava zasićeni ugljikovodični lanac koji može biti ravni lanac ili razgranati lanac, koji sadrži naznačeni broj atoma ugljika;
A process for producing a nutritional supplement according to claim 3, said process comprising admixing the bacterial species Roseburia hominis with a nutritionally acceptable excipient, carrier or diluent. 
Postupak za proizvodnju nutritivnog dodatka prema zahtjevu 3, naznačen time što sadrži miješanje bakterijske vrste Roseburia hominis sa nutritivno prihvatljivim ekscipijensom, nosačem ili diluentom.
stirring the mixture at a temperature between the freezing point and the boiling point of the mixture, adding ethanol, followed by further stirring; and, optionally, adding seed crystals, optionally followed by adding ethanol; and, optionally, filtering off the resulting dihydrochloride of formula (II), optionally washing with a water-ethanol mixture and optionally drying, 
miješanje smjese u vremenskom razdoblju od, kao što je na primjer 10 minuta, na temperaturi od između točke ledišta i točke vrelišta smjese, kao što je na primjer na sobnoj temperaturi, dodavanje etanola, nakon čega se dodatno miješa u vremenskom razdoblju, kao što je na primjer 10 minuta; te proizvoljno,
reacting a compound of Formula IIIa: with a compound of Formula IVa: under Suzuki coupling conditions to form a compound of Formula IIa: 
reakciju spoja Formule IIIa: sa spojem Formule IVa: pod Suzukijevim uvjetima spajanja da nastane spoj Formule IIa:
The pharmaceutical composition for use according to claim 9, wherein the pharmaceutical composition is prepared for dermal, mucosal, submucosal, transdermal, i.m. i.v., s.c, intradermal, oral, nasal, intraocular or suppository administration or instillation into cavities. A combination comprising: 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što farmaceutski pripravak se pripravlja za dermalnu, mukoznu, submukoznu, transdermalnu, i.m., i.v., S.c, intradermalnu, oralnu, nazalnu, intraokularnu ili supozitorijsku primjenu ili ukapavanje u šupljine.
a second separation of the polyester balls and the remaining mixture of plastic with polyester in a second sifter (T2) with aspiration; 
drugo odvajanje poliesterskih kuglica i preostale smjese plastike s poliesterom u drugom situ (T2) s aspiracijom;
There are also several physical circumstances that can induce a psychotic state, including electrolyte disorder, urinary tract infections in the elderly, pain syndromes, drug toxicity, and drug withdrawal (especially alcohol, barbiturates, and sometimes benzodiazepines), as well as infections of or injuries to the brain (these psychoses are now more commonly referred to as organic mental disorders). 
Postoji nekoliko fizičkih okolnosti koje mogu inducirati psihotičko stanje, uključujući poremećaj elektrolita, infekcije urinarnog trakta kod starijih osoba, sindrome boli, toksičnost lijekova 1 odvikavanje od lijekova (posebno alkohola, barbiturata i ponekad benzodiazepina), kao i infekcije ili ozljede mozga (te psihoze se sada češće nazivaju organskim mentalnim poremećajima).
A composition comprising S-adenosyl methionine sulphate paratoluene sulphonate or S-adenosyl methionine-1,4-butane disulphonate in association with calcium oxide and optionally pharmaceutically acceptable excipients. 
Pripravak, naznačen time što sadrži S-adenozilmetionin-sulfat-para-toluensulfonat ili S-adenozilmetionin-1,4-butan-disulfonat u smjesi s kalcijevim oksidom i izborno farmaceutski prihvatljive pomoćne tvari.
are 9 to 30, 9 to 20 or 13 to 17 amino acids in length; and/or comprises up to a maximum of thirteen polypeptides. 
- su9 do 30, 9 do 20 ili 13 do 17 aminokiselina u duljini, i/ili c) obuhvaća sve do najviše trinaest polipeptida.
an edge-reliability obtaining device configured to calculate an index for the each pixel in accordance with the magnitude of the gradient and pixel values surrounding the pixel in the band image; and 
(E) uređaj za dobivanje pouzdanosti rubova (16) koji ima konfiguraciju za izračunavanje indeksa (E) za svaki piksel u skladu s magnitudom gradijenta (m) i vrijednostima piksela koje okružuju piksel u slici na traci (a, f, mi
The human MHC I polypeptide may be selected from the group consisting of HLA-A, HLA-B, and HLA-C. In one embodiment, the human MHC I polypeptide is HLA-A2. 
Životinja prema zahtjevu 1, naznačena time, da je humani MHC-I-polipeptid odabran iz skupine koja se sastoji od sljedećih: HLA-A, HLA-B i HLA-C.
A hemihydrate according to claim 1 having an X-ray powder diffraction pattern comprising peaks, in terms of 2θ, at about 13.7°, about 14.9°, about 15.4°, about 15.8°, about 16.7°, about 20.1°, and about 21.4°. 
Hemihidrat u skladu sa zahtjevom 1, naznačen time, da ima uzorak difrakcije praha X-zrakama koji sadrži pikove, u značenju 2Θ, na oko 13.7°, oko14.9°, oko 15.4°, oko 15.8°, oko 16.7°, oko 20.1° i oko 21.4°.
The dispensing valve 30 is adapted for placement in a dispensing tap adapted to open and close the dispensing valve 30 by appropriate means (not shown) in engagement with the collars 32, 35 of the dispensing valve 30. 
Ventil za točenje 30 je prilagođen za stavljanje u pipac za točenje prilagođen tako da otvara i zatvara ventil za točenje 30 s odgovarajućim sredstvom (koje nije prikazano) u spoju s prstenovima 32, 35 ventila za točenje 30.
Preferably, such peptide comprises or consists of an amino acid sequence as indicated in SEQ ID NO: 4, in SEQ ID NO: 5, or in SEQ ID NO: 71 as the unique linear epitope recognized by the antibody or a modified sequence thereof in which one or more amino acids are substituted, deleted and/or added, wherein the peptide is recognized by any antibody of the present invention, preferably by antibody NI-203.19H8 respective by antibody NI-203.26C11 or by antibody NI-203.15C7. 
Peptid koji ima epitop IAPP-a kojeg specifično prepoznaje antitijelo u skladu s bilo kojim patentnim zahtjevom 1 do 5, naznačen time, da se peptid sastoji od 10 susjednih aminokiselina i sadržava aminokiselinsku sekvencu SSNNFGA navedenu u SEQ ID NO: 4, CNTATCA navedeni u SEQ ID NO: 5, ili QRLANFLVHS prikazani u SEQ ID NO: 71.
Still further, the invention provides a medical device where the medical device comprises a rapamycin carbohydrate derivative or a pharmaceutically acceptable salt thereof. 
Nadalje, izum daje medicinsko sredstvo, pri čemu medicinsko sredstvo obuhvaća ugljikohidratni derivat rapamicina ili njegovu farmaceutski prihvatljivu sol.
The compound of claim 34, wherein X42 is CR44, and R43 and R44, taken together with the carbon atoms to which they are attached, form a cycloalkenyl, aryl, heterocyclyl, or heteroaryl ring. 
Spoj prema zahtjevu 34, pri čemu X» je CRa 1 Rag i Ra, uzeti zajedno sa ugljikovim atomima za koje su vezani, čine cikloalkenil, aril, heterociklil ili heteroaril prsten.
The system according to claim 1, wherein the electric pump is a membrane pump that is selectively activated by the pressure switch after the injection gun is triggered to release liquid from the dosage assembly. 
Sustav prema zahtjevu 1, naznačen time da je električna pumpa membranska pumpa t koja se selektivno aktivira pomoću tlačne sklopke nakon što se pištolj za ubrizgavanje aktivira radi oslobađanja tekućine iz sklopa za doziranje.
reacting the compound of Formula V with a compound of Formula VI to give a compound of Formula VII, hydrolysing the compound of Formula VII to give a compound of Formula VIII, or hydrolysing the compound of Formula V to give a compound of Formula VII (a), reacting the compound of Formula VII (a) with a compound of Formula VI to give a compound of Formula VIII, 
reakciju spoja Formule V sa spojem Formule VI, čime se dobiva spoj Formule VII, hidroliziranje spoja Formule VII, čime se dobiva spoj Formule VIII ili hidroliziranje spoja Formule V, čime se dobiva spoj Formule VII (a), reakciju spoja Formule VII (a) sa spojem Formule VI, čime se dobiva spoj Formule VIII, [image]
A dsRNA of any one of claims 1 to 11 for use in treating in a human a disorder mediated by TTR expression, wherein 
dsRNA prema zahtjevima 1 do 8, naznačena time da je za uporabu kod liječenja čovjeka s poremećajem posredovanim s ekspresijom TTR, pri čemu
The use according to claim 8 or 9 for treating conventional or transgenic plants or seed thereof. 
Uporaba prema zahtjevu 8 ili 9 za tretiranje konvencionalnih ili transgenih biljaka ili njihovog sjemena.
An antibody or a fragment thereof that specifically binds to a CXCR4 receptor for use in a method of inhibiting growth and/or proliferation and/or inducing apoptosis of multiple myeloma cells in a subject afflicted with multiple myeloma and thereby treating the subject, wherein the CXCR4 receptor is expressed on the surface of the multiple myeloma cells in the subject and wherein the method comprises administering to the subject the antibody or fragment thereof for directly inhibiting growth and/or proliferation and/or inducing apoptosis of the multiple myeloma cells in the subject. 
HR P20182183 T1 PATENTNI ZAHTJEVI Auntitijelo ili njegov fragment koje se specifično veže za CXCR4 receptor za primjenu u metodi za inhibiranje rasta i/ili proliferacije i/ili induciranje apoptoze stanica multiplog mijeloma kod subjekta koji je pogođen multiplim mijelomom i time liječenje subjekta, gdje CXCR4 receptor je eksprimiran na površini stanica multiplog mijeloma kod subjekta i gdje metoda obuhvaća administriranje subjektu antitijela ili njegovog fragmenta za direktno inhibiranje rasta i/ili proliferacije i/ili induciranje apoptoze stanica multiplog mijeloma kod subjekta.
A pharmaceutically acceptable formulation is disclosed herein, in an embodiment, comprising about 2.5 to about 7% by weight levodopa, about 0 to about 2% by weight carbidopa, about 5 to about 18% by weight arginine, and about 0.25% to about 3% by weight ascorbic acid or a pharmaceutically acceptable salt thereof. 
Farmaceutski prihvatljiv tekući sastav sadržeći 2,5% do 7% masenog udjela levodopa; do 2% masenog udjela karbidopa; 5% do 18% masenog udjela arginina; i 0,25% do 3% masenog udjela askorbinske kiseline ili farmaceutski prihvatljive soli iste, naznačeno time da spomenuti sastav ima pH vrijednost od 9,1 do 9,8 na 25", te je molarni omjer levodopa sa karbidopom u odnosu na arginin 1:1,8 do 1:3,5.